ELLI, ELENA MARIA

ELLI, ELENA MARIA  

DIPARTIMENTO DI MEDICINA E CHIRURGIA (SCHOOL OF MEDICINE AND SURGERY)  

Mostra records
Risultati 1 - 20 di 21 (tempo di esecuzione: 0.024 secondi).
Titolo Tipologia Data di pubblicazione Autori File
Hydroxyurea-related toxicity in 3,411 patients with Ph'-negative MPN 01 - Articolo su rivista 2012 FINAZZI, MARIA CHIARAELLI, ELENA MARIAPOGLIANI, ENRICO MARIA +
Circulating endothelial cells and endothelial activation in essential thrombocythemia: Results from CD146(+) immunomagnetic enrichment-flow cytometry and soluble E-selectin detection 01 - Articolo su rivista 2012 BELOTTI, ANGELOELLI, ELENA MARIAPOGLIANI, ENRICO MARIA +
A CASE OF ATYPICAL PROLONGED HEMATOLOGIC TOXICITY WITH AZACITIDINE IN CHRONIC MYELOMONOCYTIC LEUKEMIA (CMML), REVIEW OF LITERATURE AND A PROPOSAL OF MANAGEMENT 01 - Articolo su rivista 2012 ELLI, ELENA MARIABELOTTI, ANGELOPOGLIANI, ENRICO MARIA +
Iron chelation therapy with deferasirox in the management of iron overload in primary myelofibrosis 01 - Articolo su rivista 2014 Elli E. M.Aroldi A.Pioltelli P.Pogliani E. M. +
Evidence of ETNK1 Somatic Variants in Atypical Chronic Myeloid Leukemia 02 - Intervento a convegno 2014 DONADONI, CARLAPIAZZA, ROCCO GIOVANNIFONTANA, DILETTAPIROLA, ALESSANDRAREDAELLI, SARASPINELLI, ROBERTAMAGISTRONI, VERAGAIPA, GIUSEPPEPERONACI, MARCOELLI, ELENA MARIAGAMBACORTI PASSERINI, CARLO +
Good outcome for very high risk adult B-cell acute lymphoblastic leukaemia carrying genetic abnormalities t(4;11)(q21;q23) or t(9;22)(q34;q11), if promptly submitted to allogeneic transplantation, after obtaining a good molecular remission 01 - Articolo su rivista 2015 Fumagalli, MonicaCOLNAGHI, FEDERICAElli, ElenaBelotti, AngeloCazzaniga, GiovanniPogliani, Enrico MariaPioltelli, Pietro +
Neurological symptoms in essential thrombocythemia: Impact of JAK2V617F mutation and response to therapy 01 - Articolo su rivista 2016 Aroldi A.Pioltelli P. E.Pogliani E. M.Elli E. M. +
JAK2-mutated Langerhans cell histiocytosis associated with primary myelofibrosis treated with ruxolitinib 01 - Articolo su rivista 2018 Elli E. M.L'Imperio V.Berti E. +
Paired Exome Sequencing Reveals Recurrent Germline Variants in Patients with Idiopathic Erythrocytosis 02 - Intervento a convegno 2019 Mauri, MElli, ED'Aliberti, DCrespiatico, INava, MMassimino, LFontana, DRedaelli, SBombelli, SPelucchi, SPerego, RPiperno, AGambacorti Passerini, CPiazza, R +
Integrated Genomic, Functional and Prognostic Characterization of Atypical Chronic Myeloid Leukemia (aCML) in a Cohort of 43 Patients 02 - Intervento a convegno 2019 Diletta FontanaDaniele RamazzottiAndrea AroldiLuca MassiminoElena Maria ElliMonica FumagalliRocco PiazzaCarlo Gambacorti-Passerini +
Treatment of Philadelphia-negative myeloproliferative neoplasms in accelerated/blastic phase with azacytidine. Clinical results and identification of prognostic factors 01 - Articolo su rivista 2019 Elli E.Aroldi A. +
Integrated Genomic, Functional, and Prognostic Characterization of Atypical Chronic Myeloid Leukemia 01 - Articolo su rivista 2020 Fontana, DilettaRamazzotti, DanieleAroldi, AndreaRedaelli, SaraMagistroni, VeraPirola, AlessandraMassimino, LucaMastini, CristinaBombelli, SilviaElli, Elena MariaFumagalli, MonicaPerego, Roberto APagni, FabioMologni, LucaPiazza, RoccoGambacorti-Passerini, Carlo +
Use of generic imatinib as first-line treatment in patients with chronic myeloid leukemia (CML): the GIMS (Glivec to Imatinib Switch) study 01 - Articolo su rivista 2020 Elli, Elena MariaAntolini, LauraPasserini, Carlo Gambacorti- +
Heterogeneity of the bone marrow niche in patients with myeloproliferative neoplasms: ActivinA secretion by mesenchymal stromal cells correlates with the degree of marrow fibrosis 01 - Articolo su rivista 2021 Rambaldi B.Donsante S.Di Marzo N.Dander E.Pioltelli P.Biondi A.Elli E. M.Pievani A.Serafini M. +
Being a Myeloproliferative Patient in COVID-19 Era: The Mytico Study 01 - Articolo su rivista 2021 Cavalca, FZambrotta, GPMGambacorti Passerini, CElli, EM +
Clinical and Molecular features of the patients with Idiopathic Erythrocytosis 02 - Intervento a convegno 2022 Elli, EMauri, MD’Aliberti, DCrespiatico, IFontana, DRedaelli, SPelucchi, SManghisi, BCavalca, FRipamonti, ARamazzotti, DPiperno, AGambacorti Passerini, CPiazza, R +
Large-Scale Analysis of SARS-CoV-2 Synonymous Mutations Reveals the Adaptation to the Human Codon Usage During the Virus Evolution 01 - Articolo su rivista 2022 Ramazzotti, DanieleAngaroni, FabrizioMaspero, DavideMauri, MarioD’Aliberti, DeborahFontana, DilettaAntoniotti, MarcoElli, Elena MariaGraudenzi, AlexPiazza, Rocco
Myelodysplastic Syndromes/Myeloproliferative Overlap Neoplasms and Differential Diagnosis in the WHO and ICC 2022 Era: A Focused Review 01 - Articolo su rivista 2023 Diletta FontanaElena M. ElliFabio PagniRocco Piazza
Biosimilar erythropoiesis-stimulating agents are an effective and safe option for the management of myelofibrosis-related anemia 01 - Articolo su rivista 2023 Inzoli E.Civettini I.Montelisciani L.Antolini L.Gambacorti-Passerini C.Elli E. M. +
Idiopathic erythrocytosis: a germline disease? 01 - Articolo su rivista 2024 Elli, E. M.Mauri, M.D’Aliberti, D.Crespiatico, I.Fontana, D.Redaelli, S.Pelucchi, S.Spinelli, S.Manghisi, B.Cavalca, F.Aroldi, A.Ripamonti, A.Palamini, S.Mottadelli, F.Massimino, L.Ramazzotti, D.Cazzaniga, G.Piperno, A.Gambacorti-Passerini, C.Piazza, R. +